Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD 202 data presented at 2024 EANM Annual Meeting

Wednesday, October 23, 2024 1 min read
Key Takeaway: Radiopharm Theranostics presented data on RAD 202 at the 2024 EANM Annual Meeting, showcasing advancements in their research. The company has been actively involved in clinical studies and has received positive feedback regarding its programs. This presentation marks a significant step in their ongoing efforts to develop innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of RAD 202 data indicates progress in research.
  • Participation in the 2024 EANM Annual Meeting highlights company visibility.
  • Positive clinical updates across multiple programs suggest strong pipeline.

Full Press Release Details

• Announcements
• October 23, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• March 4, 2022
• Updates
• November 27, 2024
• Announcements
• October 26, 2022
• Investor Presentations
• November 25, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What was presented at the 2024 EANM Annual Meeting?

Radiopharm Theranostics presented data on RAD 202 at the meeting.

What is the significance of RAD 202 data?

The RAD 202 data indicates progress in Radiopharm's research and development efforts.

Which company presented at the EANM Annual Meeting?

Radiopharm Theranostics presented at the 2024 EANM Annual Meeting.

What does RAD 202 relate to?

RAD 202 relates to ongoing clinical studies and therapeutic advancements by Radiopharm.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics RAD 202 EANM Annual Meeting clinical updates therapeutic study
Last updated: Oct 23, 2024